These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1804312)
1. In situ activation of mouse lung macrophages by coadministration of liposomes containing the lipopeptide CGP 31362 and interleukin 2 involves interaction with T lymphocytes and natural killer cells. Utsugi T; Dinney CP; Killion JJ; Brown D; Fidler IJ Lymphokine Cytokine Res; 1991 Dec; 10(6):487-93. PubMed ID: 1804312 [TBL] [Abstract][Full Text] [Related]
2. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362. Dinney CP; Bucana CD; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ Cancer Res; 1991 Jul; 51(14):3741-7. PubMed ID: 1905975 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Dinney CP; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ Cancer Res; 1992 Mar; 52(5):1155-61. PubMed ID: 1531322 [TBL] [Abstract][Full Text] [Related]
4. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Utsugi T; Dinney CP; Killion JJ; Fidler IJ Cancer Immunol Immunother; 1991; 33(6):375-81. PubMed ID: 1878891 [TBL] [Abstract][Full Text] [Related]
5. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18. Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477 [TBL] [Abstract][Full Text] [Related]
6. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Xie K; Huang S; Dong Z; Gutman M; Fidler IJ Cancer Res; 1995 Jul; 55(14):3123-31. PubMed ID: 7541713 [TBL] [Abstract][Full Text] [Related]
7. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ. Lala PK; Parhar RS Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954 [TBL] [Abstract][Full Text] [Related]
8. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569 [TBL] [Abstract][Full Text] [Related]
9. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674 [TBL] [Abstract][Full Text] [Related]
10. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213 [TBL] [Abstract][Full Text] [Related]
11. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Vallera DA; Taylor PA; Aukerman SL; Blazar BR Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923 [TBL] [Abstract][Full Text] [Related]
12. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801 [TBL] [Abstract][Full Text] [Related]
13. Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study. Gautam S; Deodhar S J Biol Response Mod; 1989 Oct; 8(5):560-9. PubMed ID: 2795096 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity. Hafner M; Falk W; Echtenacher B; Männel DN Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121 [TBL] [Abstract][Full Text] [Related]
15. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Gorelik E Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma. Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. Hanna N; Schneider M J Immunol; 1983 Feb; 130(2):974-80. PubMed ID: 6848604 [TBL] [Abstract][Full Text] [Related]
19. Neutralization of interleukin-2 retards the growth of mouse renal cancer. Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731 [TBL] [Abstract][Full Text] [Related]
20. Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. Nii A; Utsugi T; Fan D; Denkins Y; Pak C; Brown D; van Hoogevest P; Fidler IJ J Immunother (1991); 1991 Aug; 10(4):236-46. PubMed ID: 1931862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]